Market Research Logo

Bioprosthetics Market Analysis By Type (Allograft, Xenograft, Porcine, Bovine), By Application (Cardiovascular, Plastic Surgery & Wound Healing) And Segment Forecasts To 2024

Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
1.3. List of Data Sources
Chapter 2. Executive Summary
Chapter 3. Market Snapshot
Chapter 4. Market Variables, Trends & Scope
4.1. Market segmentation & scope
4.2. Market Driver Analysis
4.3. Market Restraint Analysis
4.4. Penetration & growth prospect mapping
4.5. Bioprosthetics-SWOT Analysis, By Factor (political & legal, economic and technological)
4.6. Industry Analysis - Porter's
Chapter 5. Market Categorization 1: Type Estimates & Trend Analysis
5.1. Bioprosthetics market: Type movement analysis
5.2. Allograft
5.2.1. Allograft Market Estimates and Forecasts, 2013 - 2024 (USD Million)
5.3. Xenograft
5.3.1. Xenograft Market Estimates and Forecasts, 2013 - 2024 (USD Million)
5.3.2. Porcine
5.3.2.1. Porcine Market Estimates and Forecasts, 2013 - 2024 (USD Million)
5.3.3. Bovine
5.3.3.1. Bovine Market Estimates and Forecasts, 2013 - 2024 (USD Million)
Chapter 6. Market Categorization 2: Application Estimates & Trend Analysis
6.1. Bioprosthetics market: Application movement analysis
6.2. Cardiovascular
6.2.1. Cardiovascular Market Estimates and Forecasts, 2013 - 2024 (USD Million)
6.3. Plastic surgery & wound healing
6.3.1. Plastic surgery & wound healing Market Estimates and Forecasts, 2013 - 2024 (USD Million)
6.3.2. Porcine
6.3.2.1. Porcine Market Estimates and Forecasts, 2013 - 2024 (USD Million)
6.3.3. Bovine
6.3.3.1. Bovine Market Estimates and Forecasts, 2013 - 2024 (USD Million)
Chapter 7. Market Categorization 3: Regional Estimates & Trend Analysis, By Type & Application
7.1. Bioprosthetics Market Share By Region, 2015 & 2024
7.2. North America
7.2.1. North America Market Estimates and Forecasts, By Type, 2013 - 2024 (USD Million)
7.2.1.1. U.S. Market Estimates and Forecasts
7.2.1.2. Canada Market Estimates and Forecasts
7.2.2. North America Market Estimates and Forecasts, By Application, 2013 - 2024 (USD Million)
7.2.2.1. U.S. Market Estimates and Forecasts
7.2.2.2. Canada Market Estimates and Forecasts
7.3. Europe
7.3.1. Europe Market Estimates and Forecasts, By Type, 2013 - 2024 (USD Million)
7.3.1.1. UK Market Estimates and Forecasts
7.3.1.2. Germany Market Estimates and Forecasts
7.3.2. Europe Market Estimates and Forecasts, By Application, 2013 - 2024 (USD Million)
7.3.2.1. UK Market Estimates and Forecasts
7.3.2.2. Germany Market Estimates and Forecasts
7.4. Asia Pacific
7.4.1. Asia Pacific Market Estimates and Forecasts, By Type, 2013 - 2024 (USD Million)
7.4.1.1. Japan Market Estimates and Forecasts
7.4.1.2. China Market Estimates and Forecasts
7.4.1.3. India Market Estimates and Forecasts
7.4.2. Asia Pacific Market Estimates and Forecasts, By Application, 2013 - 2024 (USD Million)
7.4.2.1. Japan Market Estimates and Forecasts
7.4.2.2. China Market Estimates and Forecasts
7.4.2.3. India Market Estimates and Forecasts
7.5. Latin America
7.5.1. Latin America Market Estimates and Forecasts, By Type, 2013 - 2024 (USD Million)
7.5.1.1. Brazil Market Estimates and Forecasts
7.5.1.2. Mexico Market Estimates and Forecasts
7.5.2. Latin America Market Estimates and Forecasts, By Application, 2013 - 2024 (USD Million)
7.5.2.1. Brazil Market Estimates and Forecasts
7.5.2.2. Mexico Market Estimates and Forecasts
7.6. MEA
7.6.1. MEA Market Estimates and Forecasts, By Type, 2013 - 2024 (USD Million)
7.6.1.1. South Africa Market Estimates and Forecasts
7.6.2. MEA Market Estimates and Forecasts, By Application, 2013 - 2024 (USD Million)
7.6.2.1. South Africa Market Estimates and Forecasts
Chapter 8. Competitive Landscape
8.1. Strategy framework
8.2. Market participation categorization
8.3. Company Profiles
8.3.1. LeMaitre Vascular, Inc.
8.3.1.1. Company Overview
8.3.1.2. Financial Performance
8.3.1.3. Product Benchmarking
8.3.1.4. Strategic Initiatives
8.3.2. Braile Biomedica, Inc.
8.3.2.1. Company Overview
8.3.2.2. Financial Performance
8.3.2.3. Product Benchmarking
8.3.2.4. Strategic Initiatives
8.3.3. Labcor Laboratorios Ltd.
8.3.3.1. Company Overview
8.3.3.2. Financial Performance
8.3.3.3. Product Benchmarking
8.3.3.4. Strategic Initiatives
8.3.4. Maquet Metinge Group
8.3.4.1. Company Overview
8.3.4.2. Financial Performance
8.3.4.3. Product Benchmarking
8.3.4.4. Strategic Initiatives
8.3.5. Medtronic Plc.
8.3.5.1. Company Overview
8.3.5.2. Financial Performance
8.3.5.3. Product Benchmarking
8.3.5.4. Strategic Initiatives
8.3.6. Aortech International Plc
8.3.6.1. Company Overview
8.3.6.2. Financial Performance
8.3.6.3. Product Benchmarking
8.3.6.4. Strategic Initiatives
8.3.7. CryoLife, Inc.
8.3.7.1. Company Overview
8.3.7.2. Financial Performance
8.3.7.3. Product Benchmarking
8.3.7.4. Strategic Initiatives
8.3.8. Sorin Group
8.3.8.1. Company Overview
8.3.8.2. Financial Performance
8.3.8.3. Product Benchmarking
8.3.8.4. Strategic Initiatives
8.3.9. Humacyte, Inc.
8.3.9.1. Company Overview
8.3.9.2. Financial Performance
8.3.9.3. Product Benchmarking
8.3.9.4. Strategic Initiatives
8.3.10. Ethicon, Inc.
8.3.10.1. Company Overview
8.3.10.2. Financial Performance
8.3.10.3. Product Benchmarking
8.3.10.4. Strategic Initiatives
8.3.11. LifeCell International
8.3.11.1. Company Overview
8.3.11.2. Financial Performance
8.3.11.3. Product Benchmarking
8.3.11.4. Strategic Initiatives
8.3.12. Organogenesis, Inc.
8.3.12.1. Company Overview
8.3.12.2. Financial Performance
8.3.12.3. Product Benchmarking
8.3.12.4. Strategic Initiatives
8.3.13. St. Jude Medical, Inc.
8.3.13.1. Company Overview
8.3.13.2. Financial Performance
8.3.13.3. Product Benchmarking
8.3.13.4. Strategic Initiatives
8.3.14. Edwards Lifesciences Corporation
8.3.14.1. Company Overview
8.3.14.2. Financial Performance
8.3.14.3. Product Benchmarking
8.3.14.4. Strategic Initiatives
8.3.15. JenaValve Technology GmbH
8.3.15.1. Company Overview
8.3.15.2. Financial Performance
8.3.15.3. Product Benchmarking
8.3.15.4. Strategic Initiatives
List of Tables
TABLE 1 Country share estimation
TABLE 2 North America bioprosthetics market, by type, 2013 - 2024 (USD Million)
TABLE 3 North America xenograft market, by type, 2013 - 2024 (USD Million)
TABLE 4 North America bioprosthetics market, by application, 2013 - 2024 (USD Million)
TABLE 5 U.S. bioprosthetics market, by type, 2013 - 2024 (USD Million)
TABLE 6 U.S. xenograft market, by type, 2013 - 2024 (USD Million)
TABLE 7 U.S. bioprosthetics market, by application, 2013 - 2024 (USD Million)
TABLE 8 Canada bioprosthetics market, by type, 2013 - 2024 (USD Million)
TABLE 9 Canada xenograft market, by type, 2013 - 2024 (USD Million)
TABLE 10 Canada bioprosthetics market, by application, 2013 - 2024 (USD Million)
TABLE 11 Europe bioprosthetics market, by type, 2013 - 2024 (USD Million)
TABLE 12 Europe xenograft market, by type, 2013 - 2024 (USD Million)
TABLE 13 Europe bioprosthetics market, by application, 2013 - 2024 (USD Million)
TABLE 14 Germany bioprosthetics market, by type, 2013 - 2024 (USD Million)
TABLE 15 Germany xenograft market, by type, 2013 - 2024 (USD Million)
TABLE 16 Germany bioprosthetics market, by application, 2013 - 2024 (USD Million)
TABLE 17 UK bioprosthetics market, by type, 2013 - 2024 (USD Million)
TABLE 18 UK xenograft market, by type, 2013 - 2024 (USD Million)
TABLE 19 UK bioprosthetics market, by application, 2013 - 2024 (USD Million)
TABLE 20 Asia Pacific bioprosthetics market, by type, 2013 - 2024 (USD Million)
TABLE 21 Asia Pacific xenograft market, by type, 2013 - 2024 (USD Million)
TABLE 22 Asia Pacific bioprosthetics market, by application, 2013 - 2024 (USD Million)
TABLE 23 Japan bioprosthetics market, by type, 2013 - 2024 (USD Million)
TABLE 24 Japan xenograft market, by type, 2013 - 2024 (USD Million)
TABLE 25 Japan bioprosthetics market, by application, 2013 - 2024 (USD Million)
TABLE 26 China bioprosthetics market, by type, 2013 - 2024 (USD Million)
TABLE 27 China xenograft market, by type, 2013 - 2024 (USD Million)
TABLE 28 China bioprosthetics market, by application, 2013 - 2024 (USD Million)
TABLE 29 India bioprosthetics market, by type, 2013 - 2024 (USD Million)
TABLE 30 India xenograft market, by type, 2013 - 2024 (USD Million)
TABLE 31 India bioprosthetics market, by application, 2013 - 2024 (USD Million)
TABLE 32 Latin America bioprosthetics market, by type, 2013 - 2024 (USD Million)
TABLE 33 Latin America xenograft market, by type, 2013 - 2024 (USD Million)
TABLE 34 Latin America bioprosthetics market, by application, 2013 - 2024 (USD Million)
TABLE 35 Brazil bioprosthetics market, by type, 2013 - 2024 (USD Million)
TABLE 36 Brazil xenograft market, by type, 2013 - 2024 (USD Million)
TABLE 37 Brazil bioprosthetics market, by application, 2013 - 2024 (USD Million)
TABLE 38 Mexico bioprosthetics market, by type, 2013 - 2024 (USD Million)
TABLE 39 Mexico xenograft market, by type, 2013 - 2024 (USD Million)
TABLE 40 Mexico bioprosthetics market, by application, 2013 - 2024 (USD Million)
TABLE 41 MEA bioprosthetics market, by application, 2013 - 2024 (USD Million)
TABLE 42 MEA xenograft market, by type, 2013 - 2024 (USD Million)
TABLE 43 MEA bioprosthetics market, by application, 2013 - 2024 (USD Million)
TABLE 44 South Africa bioprosthetics market, by application, 2013 - 2024 (USD Million)
TABLE 45 South Africa xenograft market, by type, 2013 - 2024 (USD Million)
TABLE 46 South Africa bioprosthetics market, by application, 2013 - 2024 (USD Million)

Bioprosthetics Market Analysis By Type (Allograft, Xenograft, Porcine, Bovine), By Application (Cardiovascular, Plastic Surgery & Wound Healing) And Segment Forecasts To 2024

The global bioprosthetics market is expected to reach USD 6.41 billion by 2024, according to a new report by Grand View Research, Inc. The unprecedented upward shift in the lifestyle-associated habits leading to the high prevalence of cardiovascular diseases coupled with the increasing geriatric population base,which is highly susceptible to developing cardiac impairments and tissue damage,are presumed to impel the demand for the bioprosthetics market during the forecast period.

Lower biocompatibility, aesthetics, and strength exhibited by the synthetic material-based prosthetics indicate the indisputable requirement for incorporating bioprosthetics; consequentially, the increasing need for the tissue-engineered autologous, allogenic or xenograft products is anticipated to present the market with lucrative growth opportunities.

The growth in the demand for bioprostheses is attributed mainly to technological advancements comprising trans catheter valve fabrication technology, the construction of which involves a multidisciplinary approach, wherein wide-ranging technologies borrowed from varied devices including balloon angioplasty and coronary stents as well as medical disciplines, such as cardiac surgery and interventional cardiology, are merged to introduce a revolutionary quantum leap in the transcatheter valve replacement procedures. Moreover, a combination of the non-invasive imaging techniques, such as, echo cardiography angiography, MRI, and CT, are increasingly being employed, which allows the surgeons to visualize both the device and the anatomy of the patient thus eliminating the need to conduct an open heart surgery.

Further key findings from the study suggest:

The allograft segment is expected to exhibit growth at a significant CAGR of over 10.0% during the forecast period. This is a consequence of the following associated advantages such as reduced surgical time, smaller incisions, greater physiological acceptability, availability of larger grafts, and a safer alternative to procedures that employ synthetic grafts as they pose a high risk of complications under anesthesia

The plastic surgery and wound healing segment is anticipated to witness an exponential CAGR of over 11.0% in the application segment over the forecast period. This substantial share can be attributed to the increasing number of soft tissue repair procedures, such as in hernia and abdominal wall reconstruction

Additionally, as per a research published by the NCBI, the increase in case complexities drive the need to apply a multidisciplinary approach in performing the above-mentioned procedures, which augments the use of these bioprosthetics meshes to decrease the morbidity associated with chronic impairments

In 2015, Europe dominated the overall bioprosthetics market at over 40.0%. Moreover, the subsequent changes in the demographic trends, such as the frequent product approvals, increasing geriatric population base, lifestyle-associated changes, and the high awareness levels pertaining to the availability of bioprosthetics solutions are anticipated to drive the market growth in this region

For instance, In April 2016, St. Jude Medical, Inc. announced the European launch of Trifecta Surgical Valve to provide enhanced alternatives to patients requiring aortic valve replacements. This launch resulted in the expansion of the existing product portfolio of St. Jude Medical, Inc. in Europe

Some leading players in this industry include Edwards Lifesciences Corporation, St.Jude Medical, Inc., Sorin Group, CryoLife, Inc., Braile Biomedica, Inc., and Medtronic Plc; these players are increasingly involved in adopting collaborative strategies and launching frequent product approvals to facilitate business expansion

For instance, in March 2016, Edwards Lifesciences Corporation received an approval for the SAPIEN 3 Valve in Japan for the treatment of patients suffering from aortic stenosis. Additionally, the rising involvement of the players in this vertical toward developing and enhancing the supply of bioprosthetics through strategic alliances is likely to provide the market with a high potential growth platform in the future


Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report

;